Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Show less

Collaborators (329)

Author information

Affiliations

  • 1. From Robarts Clinical Trials, Robarts Research Institute, Western University, London, ON (B.G.F.), University of Calgary, Calgary, AB (S.G.), and the Division of Gastroenterology and CEGIIR, University of Alberta, Edmonton (L.A.D.) - all in Canada; University of California, San Diego, La Jolla (W.J.S.), and Cedars-Sinai Medical Center, Los Angeles (S.T.) - both in California; Janssen Research and Development, Spring House (C.G., D.J., Y.L., J.R.F., J.J., L.-L.G., Y.M., O.J.A.), and Janssen Scientific Affairs, Horsham (M.A.B.) - both in Pennsylvania; the Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai (B.E.S., J.-F.C.), and New York University School of Medicine (S.K.) - both in New York; Feinberg School of Medicine, Northwestern University, Chicago (S.B.H.); University Hospitals Leuven, Leuven, Belgium (S.V., P.R.); Stellenbosch University, Stellenbosch, South Africa (W.J.V.); Semmelweis University of Budapest, Budapest, Hungary (Z.T.); the Department of Gastroenterology, Hannover Medical School, Hannover, Germany (U.S.); Atlanta Gastroenterology Specialists, Atlanta (B.A.S.); Hôpital Claude Huriez, Lille, France (P.D.); University of Washington Medical Center, Seattle (S.D.L.); and the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN (E.V.L.).
      Authors
    • Feagan BG 1
    • Sandborn WJ 1
    • Gasink C 1
    • Jacobstein D 1
    • Lang Y 1
    • Friedman JR 1
    • Blank MA 1
    • Johanns J 1
    • Gao LL 1
    • Miao Y 1
    • Adedokun OJ 1
    • Sands BE 1
    • Hanauer SB 1
    • Vermeire S 1
    • Targan S 1
    • Ghosh S 1
    • de Villiers WJ 1
    • Colombel JF 1
    • Tulassay Z 1
    • Seidler U 1
    • Salzberg BA 1
    • Desreumaux P 1
    • Lee SD 1
    • Loftus EV Jr 1
    • Dieleman LA 1
    • Katz S 1
    • Rutgeerts P 1
    (27 authors)

ORCIDs linked to this article

Show all (35)

The New England Journal of Medicine, 01 Nov 2016, 375(20):1946-1960
https://doi.org/10.1056/nejmoa1602773 PMID: 27959607 

A comment on this article appears in "[Ustekinumab for the treatment of Crohn's disease : UNITI-IM-UNITI]." Internist (Berl). 2017 Apr;58(4):424-426. A comment on this article appears in "IBD: Ustekinumab therapy for Crohn's disease." Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):4.

Abstract 

Background

Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.

Methods

We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects. The UNITI-2 trial included 628 patients in whom conventional therapy failed or unacceptable side effects occurred. Patients who completed these induction trials then participated in IM-UNITI, in which the 397 patients who had a response to ustekinumab were randomly assigned to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 8 weeks or every 12 weeks) or placebo. The primary end point for the induction trials was a clinical response at week 6 (defined as a decrease from baseline in the Crohn's Disease Activity Index [CDAI] score of ≥100 points or a CDAI score <150). The primary end point for the maintenance trial was remission at week 44 (CDAI score <150).

Results

The rates of response at week 6 among patients receiving intravenous ustekinumab at a dose of either 130 mg or approximately 6 mg per kilogram were significantly higher than the rates among patients receiving placebo (in UNITI-1, 34.3%, 33.7%, and 21.5%, respectively, with P≤0.003 for both comparisons with placebo; in UNITI-2, 51.7%, 55.5%, and 28.7%, respectively, with P<0.001 for both doses). In the groups receiving maintenance doses of ustekinumab every 8 weeks or every 12 weeks, 53.1% and 48.8%, respectively, were in remission at week 44, as compared with 35.9% of those receiving placebo (P=0.005 and P=0.04, respectively). Within each trial, adverse-event rates were similar among treatment groups.

Conclusions

Among patients with moderately to severely active Crohn's disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a clinical response to induction therapy. (Funded by Janssen Research and Development; ClinicalTrials.gov numbers, NCT01369329 , NCT01369342 , and NCT01369355 .).

Full text links 

Read article at publisher's site: https://doi.org/10.1056/nejmoa1602773

Read article for free, from open access legal sources, via Unpaywall: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1602773?articleTools=trueUnpaywall

Citations & impact 

Impact metrics

771
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/13710309
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/13710309

Article citations

Go to all (771) article citations

Data 

Data behind the article

This data has been text mined from the article, or deposited into data resources.

Clinical Trials (3)

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.